Clinical trial · no report yet · Phase 3
DeLLphi-306
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
- NCT06117774 ↗
- Active not recruiting
- Amgen
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 7 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer
- Interventions
- Tarlatamab; Placebo
- Arms
- Tarlatamab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 404
- Primary outcomes
- PFS as Determined by BICR
- OS Over the Whole Trial
- Sponsor
- Amgen
- Start
- Feb 20, 2024
- Primary completion
- Apr 20, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06117774 · updated Apr 29, 2026